The prevalences of Wuchereria bancrofti antigenaemia in communities given six rounds of treatment with diethylcarbamazine, ivermectin or placebo tablets.
The ICT filariasis card test was used to determine the prevalences of Wuchereria bancrofti antigenaemia among villagers in India. Prior to the tests, those living in the 15 study villages had been treated six times, in six rounds of mass treatment (with 54%-75% coverage) spread over 6 years, with single doses of diethylcarbamazine (five villages), ivermectin (five villages) or placebo (five villages). The corresponding overall prevalences (and ranges) of filarial antigenaemia were 20.2% (13.7%-28.6%), 22.6% (15.3%-34.3%) and 25.9% (22.6%-29.3%), respectively. The overall prevalence of antigenaemia in the villages where diethylcarbamazine (DEC) had been distributed (but not that in the 'ivermectin' villages) was significantly lower than that recorded in the 'placebo' villages (z =2.56; P <0.05). The prevalences of antigenaemia among the villagers aged 1-5 years (18.9%, 15.6% and 22.4% in the DEC, ivermectin and placebo villages, respectively) did not differ significantly with treatment (P >0.05). The results indicate that annual mass treatments based on DEC or ivermectin, with 54%-75% treatment coverage, may have only a limited effect on the prevalence of infection with adult W. bancrofti. The possible reasons for the antigenaemias observed are discussed.
Ramaiah
K D
KD
Vector Control Research Centre (Indian Council of Medical Research), Medical Complex, Indira Nagar, Pondicherry--605 006, India. ramaiah@yahoo.com
Vanamail
P
P
Pani
S P
SP
Das
P K
PK
D000818:Animals; D000947:Antigens, Helminth / Q000097:blood*; D002675:Child, Preschool; D003955:Diagnostic Tests, Routine / Q000379:methods; D004049:Diethylcarbamazine / Q000008:administration & dosage*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005368:Filariasis / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology*; D005369:Filaricides / Q000008:administration & dosage*; D006801:Humans; D007194:India / Q000453:epidemiology; D007223:Infant; D007559:Ivermectin / Q000008:administration & dosage*; D008297:Male; D010919:Placebos / Q000008:administration & dosage; D015995:Prevalence; D012423:Rural Health; D014958:Wuchereria bancrofti / Q000187:drug effects / Q000276:immunology*
D000947:Antigens, Helminth; D005369:Filaricides; D010919:Placebos; D007559:Ivermectin; D004049:Diethylcarbamazine